The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy

Answers（アンサーズ） Japan

Overview

The global race to develop ‘in vivo CAR-T therapy,’ which generates CAR-T cells directly within the patient’s body, is intensely accelerating as major pharmaceutical companies invest heavily. This innovative approach promises to overcome the high costs and complex manufacturing inherent in conventional ex vivo CAR-T, with AbbVie and Gilead already in Phase 1 trials and others like Eli Lilly and Bristol Myers Squibb aggressively acquiring biotech firms. Notably, Japan’s Astellas Pharma is engaging in international collaborations to secure its position in this cutting-edge therapeutic frontier.

In Depth

Background: Challenges of Ex Vivo CAR-T and the Promise of In Vivo Approaches

Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized cancer treatment, particularly for hematological malignancies, demonstrating unprecedented efficacy. However, current ex vivo CAR-T approaches are characterized by a complex, time-consuming, and expensive manufacturing process. This process typically involves apheresis (collecting a patient’s T cells), genetically modifying them outside the body to express a CAR, expanding these modified cells in a laboratory, and then reinfusing them into the patient. These logistical hurdles severely limit patient access, drive up healthcare costs, and present significant challenges related to cell procurement from lymphopenic patients or potential manufacturing failures.

In response, ‘in vivo CAR-T therapy’ has emerged as a highly anticipated next-generation technology. This approach involves directly administering gene-delivery vectors (e.g., viral vectors or lipid nanoparticles) into the patient to reprogram and expand endogenous (naturally occurring) T cells into CAR-T cells within the body. If successful, in vivo CAR-T could dramatically simplify the manufacturing paradigm, significantly reduce costs, shorten treatment timelines, and expand accessibility to a much broader patient population, thereby addressing a critical unmet need in oncology.

Key Findings: Intensified In Vivo CAR-T Development and Global Engagement

Entering 2026, the development of in vivo CAR-T therapy stands as one of the most fiercely competitive sectors in the global biopharmaceutical industry. Major pharmaceutical players, recognizing the transformative potential of this technology, are rapidly accelerating investments, acquisitions, and clinical development efforts across the board.

• Big Pharma’s Clinical Entry: Global pharmaceutical giants such as AbbVie and Gilead Sciences have already initiated Phase 1 clinical trials for in vivo CAR-T therapies. These early-phase trials are crucial for establishing the safety profile and preliminary efficacy of these novel approaches in human subjects, providing vital proof-of-concept for in situ gene transfer and T-cell reprogramming directly within the patient.
• Aggressive Acquisition Strategies: Other leading pharmaceutical companies, including Bristol Myers Squibb (BMS) and Eli Lilly, are employing aggressive acquisition strategies to gain a strong foothold in the in vivo CAR-T space. For instance, Eli Lilly’s recent acquisition of Kelonia Therapeutics underscores a broader industry trend of integrating specialized biotechnology capabilities to bolster internal pipelines and accelerate development. These acquisitions aim to secure cutting-edge platforms and intellectual property rather than building foundational technologies from scratch.
• Japanese Companies’ International Collaborations: Japanese pharmaceutical firms are actively participating in this global race. Astellas Pharma, for example, has entered into strategic collaborative research agreements with emerging U.S. biotechnology companies to advance in vivo CAR-T technology. This reflects a proactive approach by Japanese players to leverage global expertise, share risks, and accelerate their entry into this highly innovative therapeutic frontier, focusing on efficient development through synergistic international partnerships.
• Diverse Technical Approaches: In vivo CAR-T therapies are exploring various gene delivery systems to introduce CAR genes into T cells directly within the patient. Adeno-associated virus (AAV) vectors and lipid nanoparticles (LNPs) are prominent examples currently under investigation. Each approach has unique advantages and disadvantages concerning safety, transduction efficiency, and target cell specificity, driving ongoing research to optimize these delivery mechanisms for clinical application.

This escalating competition is primarily fueled by rapid technological advancements and the urgent need for more effective therapies, particularly against solid tumors, where conventional ex vivo CAR-T has faced significant challenges and achieved limited success.

Impact and Outlook: Reshaping Cancer Therapy and Addressing Challenges

The successful translation of in vivo CAR-T therapy promises to fundamentally transform the landscape of cancer treatment:

• Expanded Access and Cost Reduction: By dramatically simplifying the manufacturing process and eliminating the need for complex ex vivo cell manipulation, in vivo CAR-T could dramatically increase patient access globally and significantly reduce the prohibitive costs associated with current CAR-T therapies, thereby enhancing healthcare equity worldwide.
• Potential for Solid Tumor Efficacy: While ex vivo CAR-T has excelled in hematological cancers, its application in solid tumors has been challenging due to issues like T-cell infiltration, persistence, and function within the immunosuppressive tumor microenvironment. In vivo approaches may offer novel strategies to overcome these hurdles, potentially leading to breakthroughs in solid tumor indications.
• Managing Safety Profiles: A critical challenge remains in precisely controlling the in vivo gene transduction and subsequent T-cell expansion to effectively manage potential adverse effects such as cytokine release syndrome (CRS) and neurotoxicity. Precision control over vector dosage, T-cell activation, and target specificity will be crucial for ensuring patient safety and treatment efficacy.
• Regulatory Alignment: Establishing appropriate regulatory guidelines for this entirely novel therapeutic modality is essential for its efficient development and deployment. Close collaboration with regulatory agencies, informed by early clinical data and emerging safety profiles, will be key to expediting approvals and bringing these treatments to patients.

Though still in its nascent stages, the potential benefits of in vivo CAR-T therapy are immense. Global research and development efforts, including those spearheaded by Japanese companies through strategic international partnerships, are poised to bring this revolutionary treatment to fruition, offering new hope in the ongoing fight against cancer.